Taxanes for adjuvant treatment of early breast cancer-Reference-Cited by-同舟云学术

Taxanes for adjuvant treatment of early breast cancer

Published:2007-10-17 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Ferguson Thomas¹,Wilcken Nicholas²,Vagg Rosemary³,Ghersi Davina⁴,Nowak Anna K⁵

Affiliation:

1. Sir Charles Gairdner Hospital; Department of Medical Oncology; Monash Avenue Nedlands WA Australia 6009

2. Westmead and Nepean Hospitals; Medical Oncology; Department of Medical Oncology and Palliative Care Westmead Hospital Westmead NSW Australia 2145

3. National Breast Cancer Centre; Research; Level 4, 92 Parramatta Road Camperdown NSW Australia 1450

4. NHMRC Clinical Trials Centre, The University of Sydney; Systematic Reviews and Healthcare Assessment; Locked Bag 77 Camperdown NSW Australia 1450

5. Sir Charles Gardiner Hospital and University of Western Australia; Department of Medical Oncology; B Block, Hospital Avenue Nedlands Perth WA Australia 6099

Publisher

Wiley

Subject

Pharmacology (medical)

Reference44 articles.

1. Adjuvant Docetaxel for Node-Positive Breast Cancer;Martin;The New England Journal of Medicine,June 2005

2. Crown JP Francis P Di Leo A Docetaxel given concurrently with or sequentially to anthracycline-based adjuvant therapy for patients with node-positive breast cancer, in comparison with non-taxane combination chemotherpy: First results of the BIG 2-98 Trial at 5 years median follow-up Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part 1. Vol 24, No. 18S June 2006 LBA519

3. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer;Henderson;Journal of Clinical Oncology, Vol 21, No. 6.,March 2003

4. Goldstein L O'Neill A Sparano J E2197: Phase 3 AT vs. AC in the adjuvant treatment of node positive and high risk node negative breast cancer Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Abstract 512. 2005

5. Gianni L Baselga J Eiermann W European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression from adding paclitaxel to doxorubicin followed by cyclophosphamide methotrexate and flurouracil Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consenso mexicano de cáncer mamario. Manejo del cáncer de mama temprano;Gaceta Mexicana de Oncolog�a;2024-06-25

2. A Comprehensive Review of Taxane Treatment in Breast Cancer: Clinical Perspectives and Toxicity Profiles;Cureus;2024-04-29

3. Mechanisms of platinum-induced peripheral neuropathy in cancer patients;Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova;2023

4. Breast cancer therapy in women under 35 years and between 50 and 69 years: influence of the observation period;Journal of Cancer Research and Clinical Oncology;2022-12-20

5. A systemic review of taxanes and their side effects in metastatic breast cancer;Frontiers in Oncology;2022-10-11